Tariff threat won't blunt India's edge in pharma exports: Experts

25% duty unlikely if reciprocal policy is followed, say analysts

- Mukesh Jagota

The threat by US President Donald Trump to impose "25% or higher" import duties on pharmaceutical products for countries across the board is unlikely to have a major adverse impact on India, as the country is the lowest-cost supplier with nearly unbeatable competitive advantage, industry sources and analysts said. The optimism is despite the fact that the US is the largest overseas market for India's branded generics, and accounts for more than a fourth of the country's exports of medicines and vaccines.